These are promising results, but the studys authors note that more research is needed, and clinicians must also consider potential adverse effects, evaluate the cost-effectiveness of these medications for each patient, and closely monitor for any improvement or worsening of eating disorders and related side effects. That hesitation is shared by the National Eating Disorder Association (NEDA), who published an opinion paper on GLP-1s and eating disorders in 2024, stating: While there is some evidence that GLP-1s can decrease the number of binge eating episodes for those with BED, little is known about the long term physical and psychological impact on those with eating disorders. How GLP-1s could also fuel eating disorders The same mechanisms that make these medications helpful for some could make them harmful for others
They are ideal for detecting very recent drug use, from a few hours up to a couple of days, making them useful for quick screenings like roadside tests
Both are administered as once-weekly injections and may help eligible patients reduce appetite, improve portion control, and support meaningful weight loss when combined with nutrition and lifestyle changes
Disclaimer: GLP1 R is intended strictly for laboratory research and invitro use only
Key Takeaways Initial metabolic changes appear first: Appetite suppression, reduced calorie intake, and improved glucose control typically show up in the first 14 weeks
